WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next generation…
WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site
WuXi STA, a renowned Contract Research, Development, and Manufacturing Organization (CRDMO), made a groundbreaking announcement recently. The company has initiated a high potency, fully automated sterile injectable manufacturing line at its Wuxi City site, upping its manufacturing capabilities and capacity…
